Sigrid Therapeutics AB was founded in 2014 by Tore Bengtsson and Sana Alajmovic, with the vision of transforming the way modern day chronic lifestyle diseases are treated and prevented.

The company has developed a novel materials platform technology, SiPore, which targets lifestyle diseases by changing the way our bodies digest food. The lead product candidate, SiPore15, is being developed as the first therapy acting in the gut to improve blood sugar levels in people at risk of developing diabetes.

Sigrid Therapeutics is part of the Karolinska Innovations incubator Drive for promising life science startups in Sweden.

We spoke with Alajmovic, the CEO and co-founder of Sigrid, at NLS Days in Malmö, Sweden.

➡ Subscribe to our newsletter: https://bit.ly/3kHyfKc
➡ Get more biotech news:
Official site: https://bit.ly/3OJgYzi
Linkedin:   / 5312453  
Twitter:   / labiotech_eu  
Facebook:   / labiotech.eu  
Instagram:   / labiotech.eu  

About Labiotech.eu:
Labiotech.eu is an online publication covering the global biotech industry, with a mix of news and in-depth analysis. Updated daily, the site also includes a weekly podcast.

@sigridtherapeutics5605
#biotech #sweden #lifestylediseases #diabetes